Bartholomew C, Kilbey A, Clark A M, Walker M
The Beatson Institute for Cancer Research, Glasgow, Scotland.
Oncogene. 1997 Feb 6;14(5):569-77. doi: 10.1038/sj.onc.1200864.
The myeloid transforming gene Evi-1 encodes a protein with two zinc finger domains, designated ZF1 and ZF2, with distinct DNA binding specificities. For the first time we demonstrate that Evi-1 has transcriptional repressor activity which is directly proportional to the amount of Evi-1 protein in cells. Repression has been observed with two distinct promoters: the minimal HSV-1 tk promoter and a VP16 inducible adenovirus E1b minimal promoter. Optimal repression is DNA binding dependent and is mediated by either ZF1 or a heterologous GAL4 DNA binding domain (GAL4DBD) but is significantly less efficient through the ZF2 binding site. Both GAL4DBD/Evi-1 fusion and non-fusion proteins have been used to map the repressor activity to a proline-rich region located within amino acids 514-724 between the ZF1 and ZF2 domains. Constitutive expression of mutant proteins lacking the repressor domain are defective for transformation of Rat1 fibroblasts demonstrating that this region is required for the oncogenic activity of the Evi-1 protein. These studies show that the Evi-1 gene encodes a transcriptional repressor and has important implications for the mechanism of action of the Evi-1 protein both in development and in the progression of some myeloid leukaemias.
髓系转化基因Evi-1编码一种具有两个锌指结构域的蛋白质,分别命名为ZF1和ZF2,它们具有不同的DNA结合特异性。我们首次证明Evi-1具有转录抑制活性,且该活性与细胞中Evi-1蛋白的量成正比。在两个不同的启动子上观察到了抑制作用:最小单纯疱疹病毒1型胸苷激酶启动子和VP16诱导的腺病毒E1b最小启动子。最佳抑制作用依赖于DNA结合,由ZF1或异源GAL4 DNA结合结构域(GAL4DBD)介导,但通过ZF2结合位点的效率明显较低。GAL4DBD/Evi-1融合蛋白和非融合蛋白均已用于将抑制活性定位到位于ZF1和ZF2结构域之间氨基酸514-724内的富含脯氨酸的区域。缺乏抑制结构域的突变蛋白的组成型表达对Rat1成纤维细胞的转化有缺陷,表明该区域是Evi-1蛋白致癌活性所必需的。这些研究表明,Evi-1基因编码一种转录抑制因子,对Evi-1蛋白在发育和某些髓系白血病进展中的作用机制具有重要意义。